title: Mammalian target of rapamycin as a target in hematological malignancies.
abstract: The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
authors.affiliation: Institute for Drug Development, Cancer Therapy & Research Center, University of Texas Health Science Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA. KellyKR@uthscsa.edu
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kelly
authors.forename: Julie H
authors.initials: JH
authors.lastname: Rowe
authors.forename: Swaminathan
authors.initials: S
authors.lastname: Padmanabhan
authors.forename: Steffan T
authors.initials: ST
authors.lastname: Nawrocki
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Carew
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus